Argenica Therapeutics Ltd
Argenica Therapeutics Ltd
Your view on AGN.AX
Overview
What the company does, where it operates, and who runs it.
About Argenica Therapeutics Ltd
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Liz Dallimore
- Headquarters
- 117 Broadway, Nedlands, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Liz Dallimore
- Headquarters
- 117 Broadway, Nedlands, WA, AU
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury.
The company was incorporated in 2019 and is based in Nedlands, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Argenica Therapeutics Ltd. Starting points for Argenica Therapeutics Ltd: EPS -AUD 0.01, beta 0.71 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Argenica Therapeutics Ltd. Argenica Therapeutics Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Argenica Therapeutics Ltd. Trailing twelve-month EPS for Argenica Therapeutics Ltd stands at -AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | −AUD 0.07 | AUD 0.21 |
| Lowest estimate | −AUD 0.07 | AUD 0.21 |
| Highest estimate | −AUD 0.07 | AUD 0.21 |
| Number of analysts | 1 | 1 |
| A year ago | −AUD 0.011 | — |
| Growth vs a year ago | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | AUD 28.10M | AUD 6.70M |
| Lowest estimate | AUD 28.10M | AUD 6.70M |
| Highest estimate | AUD 28.10M | AUD 6.70M |
| Number of analysts | 1 | 1 |
| A year ago | AUD 0.00 | — |
| Growth vs a year ago | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Argenica Therapeutics Ltd. Argenica Therapeutics Ltd has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ADO.AXAnteoTech Limited | Basic Materials | Chemicals - Specialty | — | ||
| BDX.AXBCAL Diagnostics Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| EMD.AXEmyria Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| EYE.AXNova Eye Medical Limited | Healthcare | Medical - Devices | — | ||
| IIQ.AXINOVIQ Ltd | Healthcare | Medical - Diagnostics & Research | — | ||
| IMC.AXImmuron Limited | Healthcare | Biotechnology | — | ||
| MAP.AXMicroba Life Sciences Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| NOX.AXNoxopharm Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PFNDPathfinder Cell Therapy, Inc. | Healthcare | OTC | $66,716 | ||
| PGENPrecigen, Inc. | Healthcare | NASDAQ | $1.5B | ||
| PHARPharming Group N.V. | Healthcare | NASDAQ | $882.4M | ||
| PHATPhathom Pharmaceuticals, Inc. | Healthcare | NASDAQ | $430.8M | ||
| PHGUFPharming Group N.V. | Healthcare | OTC | $1.1B | ||
| PHIOPhio Pharmaceuticals Corp. | Healthcare | NASDAQ | $8.6M | ||
| PHMMFPharma Mar, S.A. | Healthcare | OTC | $1.5B | ||
| PHRM.CNPharmaTher Holdings Ltd. | Healthcare | CNQ | $9.1M | ||
| PHRRFPharmaTher Holdings Ltd. | Healthcare | OTC | $5.3M | ||
| PHVSPharvaris N.V. | Healthcare | NASDAQ | $2.2B | ||
| PHYOFIXICO plc | Healthcare | OTC | $6.5M | ||
| PKTXProtoKinetix, Incorporated | Healthcare | OTC | $2.7M | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Argenica Therapeutics Ltd.